Effect of Ranolazine on Ischemic Myocardium IN Patients With Acute Cardiac Ischemia (RIMINI-Trial): A Randomized Controlled Pilot Trial

Abstract

In conclusion, in this preliminary hypothesis-driven study, 6-week ranolazine therapy was shown to decrease the area of dyskinetic myocardium in patients with ACS by trend. Global strain rate measurement using speckle-tracking echocardiography can be applied measuring those effects and is, compared to other techniques, safe and harmless. Our data provide a sound basis for a follow-up trial.

Effect of ranolazine on plasma arginine derivatives and urinary isoprostane 8-iso-PGF2α in patients with myocardial infarction in the randomized RIMINI-Trial

“…Twenty patients were enrolled in the study. Participants’ characteristics at baseline and during the study are presented in Table 1 and in 22 . Even though patients randomized to ranolazine tended to present a lower systolic blood pressure in the course of the study, diastolic blood pressure was not different to control patients.…”

“…For study details please refer to 22 and the Supplemental File. In short, the study was performed in a two-armed, controlled, and randomized way.…”

“…Ranolazine has been approved for CAD treatment. We recently showed in a preliminary hypothesis-driven study (NCT01797484, ClinicalTrials.gov) that six-week ranolazine therapy decreased the area of dyskinetic myocardium in patients with ACS by trend 22 . Previous animal studies have shown an additional vasodilatory effect of ranolazine in aortic rings 23 .…”

Through the heart and beyond: a review on ranolazine

“…The finding of this study was that patients who were in treatment with ranolazine, had a tendency to higher normal fraction of the global strain than patients who were not. Therefore, adding ranolazine to the standard therapy in patients with ACS, showed effectiveness in decreasing the dyskinetic myocardium area [8]. Some clinical evidences showed the effectiveness of the ranolazine in patients with non-obstructive coronary arteries and in symptomatic patients already undergone to PCI.…”

“…Ranolazine in the MERLIN TIMI 36 showed a reduction of the risk of relapsing ischemia in patients with non-ST-elevation ACS by probably improving myocardial perfusion. Following this observation, Schwemer et al [8] assumed that the administration of ranolazine during the first phase of an acute coronary syndrome, by the enhancement of myocardial microcirculation, should probably lead to a recruiting and recovering of hibernating myocardium activity. They published atrial (RIMINI-Trial), designed in order to demonstrate that ranolazine, added to standard therapy for six weeks, should be able to reduce the extension of myocardial ischemia in patients suffering from ACS.…”